Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen

AIDS

Volumn 12, Issue 11, 1998, Pages 1291-1300

  Bartlett, John A ^a   Wasserman, Steven S ^b   Hicks, Charles B ^a   Dodge, Robert T ^a   Weinhold, Kent J ^a   Tacket, Carol O ^b   Ketter, Nzeera ^c   Wittek, Alec E ^d   Palker, Thomas J ^a   Haynes, Barton F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d PFIZER INC   (United States)

Author keywords

Antibodies; Cellular immunity; Envelope proteins; Vaccine

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; FREUND ADJUVANT; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; SYNTHETIC PEPTIDE; VIRUS ANTIGEN;

ADULT; ANTIBODY TITER; APPENDICITIS; ARTICLE; B LYMPHOCYTE; CARPAL TUNNEL SYNDROME; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; MYALGIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; VIRUS ISOLATION;

EID: 0005020368     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00010     Document Type: Article

References (27)

1. Haynes BF: HIV vaccines: where we are and where we are going. Lancet 1996, 348:933-937.
2. Ward FE, Tuan S, Haynes BF: Analysis of HLA frequencies in population cohorts for design of HLA-based HIV vaccines. In HIV Molecular Database 1995. Edited by Korber B, Brander C, Walker B, Koup R, Moore J, Haynes B, Myers G. Los Alamos: Theoretical Biology Group, Los Alamos National Laboratory: 1995:IV10-IV16.
3. Palker T, Matthews T, Langlois A, et al.: Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol 1989, 142:3612-3619.
4. Palker T, Clark M, Langlois A, et al.: Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988, 85:1932-1936.
5. Safrit J, Lee A, Andrews C, Koup R: A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients. J Immunol 1994, 153:3822-3830.
6. Haynes BF, Moody MA, Heinly CS, et al.: HIV-1 gp120 V3 region primer-induced antibody suppression is overcome by administration of HIV-1 gp120 envelope C4-V3 peptides as a polyvalent immunogen. AIDS Res Hum Retroviruses 1995, 11:211-221.
7. Hart MK, Palker T, Matthews T, et al.: Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 1990, 145:2677-2685.
8. Haynes B, Torres J, Langlois A, et al.: Induction of HIV MN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J Immunol 1993, 151:1646-1653.
9. Hart MK, Weinhold K, Scearce R, et al.: Priming of anti-human immunodeficiency virus HIV CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci USA 1991, 88:9448-9452.
10. Yasutomi Y, Palker TJ, Gardner MB, et al.: Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993, 151:5096-5105.
11. de Lorimier R, Moody MA, Haynes BF, Spicer LD: NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. Biochemistry 1994, 33:2055-2061.
12. Ahearne PM, Matthews TJ, Lyerly HK, White GC, Bolognesi DP, Weinhold KJ: Cellular immune response to viral peptides in patients exposed to HIV. AIDS Res Hum Retroviruses 1988, 4:259-267.
13. Ahearne P, Morgan R, Sebastian M, et al.: Multiple CTL specificities against autologous HIV-1 infected BLCLs. Cell Immunol 1995, 161:34-41.
14. Ferrari G, Humphrey W, McElrath MJ, et al.: Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997, 94:1396-1401.
15. Graham B, Matthews T, Belshe M, et al.: Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1993, 167:533-537.
16. Redfield RR, Birx DI, Ketter N, et al.: A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl J Med 1991, 324:1677-1684.
17. 3. Presented at the IX International Conference on AIDS. Berlin, June 1993.
18. Travger R, Fevre F, Daigle A: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994, 169:1256-1264.
19. Schooley R, Spino C, Chiu S, DeGruttola V, Kuritzkes D for the ACTG 209 and 214 Study Teams: Poor immunogenicity of HIV-1 envelope vaccines with alum or MF59 adjuvant in HIV-infected individuals: results of two randomized trials. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 756].
20. Page W, Norman J, Benenson A: Long-term follow-up of army recruits immunized with Freund's incomplete adjuvanted vaccine. Vaccine Res 1993, 2:141-149.
21. Staats HF, Nichols WG, Palker TJ: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10MN(A). J Immunol 1996, 157:462-472.
22. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ: Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 1997, 158:834-841.
23. Eron J, Ashby M, Giordano M, et al.: Randomized trial of MN rgp120 HIV vaccine in symptomless HIV infection. Lancet 1996, 348:1541-1551.
24. Stanely S, Ostrowski M, Justement J, et al.: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996, 334:1222-1230.
25. Haynes BF: New frontiers for immunotherapy of HIV infection. Lancet 1996, 348:1531-1532.
26. Kelleher A, Emery S, Cunningham P, et al.: Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res Hum Retroviruses 1997, 13:29-39.
27. Rubinstein A, Goldstein H, Pettoello-Mantuvani M, et al.: Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS 1995, 9:243-251.